InvestorsHub Logo
Followers 0
Posts 127
Boards Moderated 0
Alias Born 04/21/2011

Re: None

Thursday, 08/31/2017 3:58:55 AM

Thursday, August 31, 2017 3:58:55 AM

Post# of 3283
PFS 4.04 months, DCR 75.49%, ORR 18.8% - those are the results of the korean BC study.

Not as good as i hoped but in this 3rd line setting oft HER2 directed therapies = "clinical meaningful" which means in physicians language that this is approvable if they can confirm the results in a larger randomized pivotal study.

So i am not disappointed. Maybe the find a biomarker to boost results in a Subpopulationen for a much faster path to market.